Index

A
Acne therapy, 73
Adenoma
  follicular, 1, 65, 76
dystrophic degeneration of, 103
distinguished from colloid-predominant lesions, 58
Hurthle cell, 88, 89, 93
distinguished from Hurthle cell carcinoma, 89, 91, 101
parathyroid
cystic, 115, 116
differential diagnosis of, 82–83
distinguished from Hurthle cell neoplasms, 100
multiple endocrine neoplasia associated with, 148
with oncocytic features, 100
Adenomatous thyroid nodules
  cellular, 64–65, 67, 71, 67–73
degenerative changes in, 73
diagnostic criteria for, 67, 71, 67–73
diagnostic pitfalls regarding, 82–83
clinical management of, 62–63
as colloid-predominant, nonneoplastic nodules, 51–52
cystic degeneration of, 24, 58, 59, 103–104, 105, 107, 108
diagnostic criteria for, 56–58
distinguished from follicular variant papillary carcinoma, 131
 follicular epithelium of, 56–57
giant cells in, 46–47
Hurthle cells in, 56, 57, 58, 89–92
with oncocytic features, distinguished from Hurthle cell neoplasms, 88–89, 95, 96, 97, 98
thin-layer preparations of, 60–62, 63
Air-drying, of specimens, 18
  as artifact cause, 21
effect on colloid, 52, 54
Algorithmic diagnostic approach, 21–28. See also under specific thyroid lesions

Amyloid
Cong red staining of, 155–156
distinguished from amyloid goiter, 155–156, 156
colloid, 155
in medullary thyroid carcinoma, 148, 151, 152, 154–155, 156, 161

Anaplastic thyroid carcinoma. See Undifferentiated (anaplastic) thyroid carcinoma

Anaplastic variant, of medullary thyroid carcinoma, 154

Ancillary diagnostic techniques. See also
Immunocytochemistry; Immunophenotyping for colloid-predominant lesions, 60, 62
for cystic lesions, 117–118
for follicular lesions, 85–86
for Hurthle cell neoplasms, 100–101
for inflammatory lesions, 48
for medullary thyroid carcinoma, 148, 160–161
for papillary thyroid carcinoma, 143–144
for undifferentiated (anaplastic) thyroid carcinoma, 177

Artifacts
in air-dried specimens, 21
colloid-related, 52, 54, 55

Aspirin, discontinuation prior to FNA, 17
Azkanazy cells, 88

B
Bacterial infections, as acute thyroiditis cause, 31, 34–35
Benign, as diagnostic category, 26
Black thyroid, 73, 74
Bleeding disorders, as FNA contraindication, 16–17
Blood. See also Hematoma; Hemorrhage in FNA specimens, 13–14, 18
in thyroid cysts, 106, 107
Blood vessels, transgressing, in Hurthle cell neoplasms, 94, 95
B lymphocytes, in Hashimoto’s thyroiditis, 35

BRAF gene mutations, 120, 143
Branchial cleft-like (lymphoepithelial) cysts, 103, 104, 114–115
distinguished from follicular-derived thyroid cysts, 117
Breast cancer, metastatic to the thyroid, 164, 172–173, 176

C
Calcification
dystrophic, 130
in follicular lesions, 73
Calcitonin
as medullary thyroid carcinoma marker, 147, 157, 160–161, 175
postoperative monitoring of, 162
as papillary thyroid carcinoma marker, 143
Carcinoembryonic antigen (CEA)
as medullary thyroid carcinoma marker, 160, 161, 175
postoperative monitoring of, 162
negative correlation with undifferentiated carcinoma, 175, 177
as papillary thyroid carcinoma marker, 143
as ultimobranchial body cyst marker, 114–115, 117–118
C cells, parafollicular, 147
CD5, 43, 44
CD10, 43, 44, 175, 177
CD15, 143
CD20, 43, 44
CD23, 43, 44
CD45, 44
Cell blocks, processing of, 18
Centroblast-like cells, in diffuse large B-cell lymphoma, 41
Centroblasts, in Hashimoto’s thyroiditis, 35
Centrocyte-like cells, in mucosa-associated lymphoid tissue lymphoma, 43
Centrocytes, in Hashimoto’s thyroiditis, 35
Cholesterol crystals, 111, 114
Diff-Quik staining of, 106
Chromatin
in cellular adenomatous nodules, 69, 73
clumped, in undifferentiated thyroid carcinoma, 167, 168, 169,
in cyst lining cells, 110
in diffuse large B-cell lymphoma, 41, 42
granular, in adenomatous nodules, 58
in insular carcinoma, 81
in papillary thyroid carcinoma, 58, 121, 157
thin-layer preparation appearance of, 144
“salt-and-pepper,” in medullary thyroid carcinoma, 151, 152, 157
in ultimobranchial body cysts, 115
Chromogranin
as medullary thyroid carcinoma marker, 160, 161, 175
negative correlation with undifferentiated carcinoma, 175, 177
as papillary thyroid carcinoma marker, 143
CK7, as medullary thyroid carcinoma marker, 175
CK20+, as metastatic colon carcinoma marker, 175, 177
Clear cell changes, in follicular neoplasms, 79
Clear cells, in medullary thyroid carcinoma, 153–155
Clear cell variant, of medullary thyroid carcinoma, 155
Collagenous bodies, in Hashimoto’s thyroiditis, 35
Collagenous fibrous tissue, in Reidel’s thyroiditis, 40, 42
Colloid
  in adenomatous nodules, 24, 57, 69, 71, 72, 73, 96
  brown pigment granules in, 73
  in colloid nodules, 24
  cracking artifacts in, 54, 55
  definition of, 24
  “dense,” 54, 60, 62, 63
distinguished from amyloid, 155–156
  in follicular thyroid neoplasms, 77, 79
  in Hashimoto’s thyroiditis, 35
  in Hurthle cell neoplasms, 92
  identification of, 52
  “ropey”/”bubble gum” appearance of, 128
  “tissue-paper-like,” 60, 61, 62
  variable appearance of, 52
  “watery,” 23, 54, 55, 60, 62
  in benign thyroid cysts, 107
  in thin-layer preparations, 60, 61, 62
  in thyroid cysts, 106, 107, 107, 108, 116
Colloid-predominant lesions, 24, 51–63. See also Goiter
  ancillary diagnostic techniques for, 60, 62
  clinical management of, 62–63
  diagnostic criteria for, 52–58
  diagnostic pitfalls regarding, 58–59
differential diagnosis of, 58–59
general diagnostic approach to, 52
  prognosis for, 62–63
Colorectal cancer, metastatic to the thyroid, 164, 172–173, 177
Congo red stain, for amyloid, 161
Cowden’s syndrome, 64
Cyclin D1, 44, 45
Cystic degeneration, of thyroid nodules. See also Cysts, thyroid of adenomatous nodules, 24, 58, 59, 103, 105, 107, 108
  of follicular nodules, 107–110
Cystic papillary thyroid carcinoma, 59, 103, 104, 110–112, 116–117, 121
Cyst lining cells, 108–110, 117
Cystic papillary thyroid carcinoma, 59, 103, 104, 110–112, 116–117, 121
Cysts, thyroid, 1, 24, 103–119
  algorithmic diagnostic approach to, 105
  benign, 107–108
  branchial cleft-like cysts, 103, 104, 114–115, 117
distinguished from follicular-derived cysts, 117
  causes of, 103
  clinical management of, 118–119
diagnostic criteria for, 104–116

differential diagnosis of, 105, 116–117

drainage of, 13–14

false-negative diagnosis of, 103, 107

follicular-derived, 73, 103, 104–105, 117

general diagnostic approach to, 104

general features of, 104–107

“less than optimal” (nondiagnostic) specimens of, 24, 106–107

malignant, 103, 106

nonfollicular-derived, 103, 104

papillary thyroid carcinoma-associated, 23–24, 59, 110–112

parathyroid cysts, 103, 104, 115–116, 117

thyroglossal duct cysts, 103, 104, 113–114

distinguished from follicular-derived thyroid cysts, 117

ultimobranchial body cysts, 104, 114–115, 117

Cytokeratin

as medullary thyroid carcinoma marker, 159–160, 161–162

as papillary thyroid carcinoma marker, 143

as undifferentiated thyroid carcinoma marker, 175, 177

Cytoplasm

basophilic, in diffuse large B-cell lymphoma, 41

foamy

in subacute thyroiditis, 38

in thyroid cysts, 106, 107

granular

in Hashimoto’s thyroiditis, 37, 38

in Hurthle cell neoplasms, 91–92

in Hurthle cells, 139

in subacute thyroiditis, 38

in Warthin’s-like papillary thyroid carcinoma, 134, 135

in Hurthle cell neoplasms, 91, 92, 100

in papillary thyroid carcinoma, 124, 127

pink, 136

“squamoid,” 124, 128

vacuolated, in Graves’ disease, 139, 140

“waxy,” 124

Cytospins, 55

processing of, 18

D

Diagnostic categories, in fine-needle aspiration, 26–28

Diagnostic findings, reports of, 26, 28

Diff-Quik stain preparations of cholesterol crystals, 106–107

colloid in, 54

of papillary thyroid carcinoma, 126, 127
Dipeptidyl aminopeptidase, as follicular thyroid lesion marker, 85
Direct smears, processing of, 18, 19–20

E
Eosinophils, in subacute thyroiditis, 38
Epithelial cells
ciliated respiratory, 15–17
in cystic papillary thyroid carcinoma, 111, 112, 117
in medullary thyroid carcinoma, 148, 150–151
in thyroglossal duct cysts, 113
Epithelium-predominant lesions, 24
Epitheloid neoplasms, distinguished from subacute thyroiditis, 38
Equipment, for fine needle aspiration, 12
Ethanol fixation, of specimens, 18
colloid in, 54, 55

F
Fibrosis
in follicular lesions, 73
Hashimoto’s thyroiditis-related, 35
Fine needle aspiration (FNA)
accuracy of, 3–4
benefits of, 2
comparison with frozen section diagnosis, 3
complications of, 15–16
contraindications to, 16–17
cost-effectiveness of, 2
diagnostic applications of, 1
diagnostic categories in, 26–28
diagnostic reports in, 26, 28
false-positive and false-negative diagnoses in, 4
nondiagnostic rate in, 24
performance of, 7–17
clinical history evaluation prior to, 9–10
physical examination prior to, 10–12
pre-FNA evaluation prior to, 7–12
post-FNA care in, 14–15
procedure for, 10–11, 12–15
specimen processing in, 17–20
of cell blocks, 18
of Cytospins, 18
of direct smears, 18, 19–20
of thin-layer preparations, 19–20
as thyroid cancer screening test, 2
ultrasound-guided, 8, 9, 104, 106
Flame cells, 72, 73, 74
Flow cytometry, of lymphoma, 43, 48, 174
FNA. See Fine needle aspiration
Follicles. See also Follicular cells; Macrofollicles; Microfollicles
diameter of, 53, 56–57
Follicular cells
adequate number of, in FNA specimens, 21, 24
enlarged nuclei in, 138–139
in Graves’ disease, 74–76
in Hashimoto’s thyroiditis, 96
with oncocytic features. See Hurthle cells
Follicular thyroid carcinoma, 64–87
algorithmic diagnostic approach to, 65, 66
classification of, 4–5, 64
clinical management of, 86–87
cystic, 104
distinguished from Graves’ disease, 74
incidence of, 2–3, 64
invasiveness of, 64
metastatic, 86
as percentage of all thyroid carcinomas, 64
prognosis for, 86–87
relationship with goiter, 64
risk factors for, 64
screening test for, 64–65, 67
Follicular thyroid lesions
cellular adenomatous nodules as, 67, 71, 67–73
cystic degeneration of, 107–110
diagnostic pitfalls regarding, 82–83
differential diagnosis of, 83–85, 134–135
Hurthle cells in, 89
with oncocytic changes, 135
Follicular thyroid neoplasms
cystic degeneration of, 107
cytodarchitectural patterns of crowded, three-dimensional, 79
nonmacrofollicular, 77
trabecular, 78, 79
cytologic features of, 58
distinguished from cellular adenomatous nodules, 82
follicular variant papillary carcinoma, 131
with oncocytic features, Hurthle cell neoplasms as, 88–89
“suspicious for” diagnostic category of, 76–79, 86
variants of, 79–80
Follicular variants of medullary thyroid carcinoma, 154–155
of papillary thyroid cancer, 65, 83, 121, 131–133
of papillary thyroid carcinoma
nuclear features of, 82–83, 131, 133
Foreign-body reactions, 46, 47
Fungal infections, as acute thyroiditis cause, 31
G
Galectin-3
as follicular thyroid lesions marker, 85
as medullary thyroid carcinoma marker, 160
as papillary thyroid carcinoma marker, 143
Ganglioneuroma, mucosal, 148
Genetic screening, for familial medullary thyroid carcinoma, 161
Giant cells
differential diagnosis of, 47
epitheloid, in cystic papillary thyroid carcinoma, 111
in Hashimoto’s thyroiditis, 35
in medullary thyroid carcinoma, 153–154
Giant cells (cont.)
multinucleated
in cystic papillary thyroid carcinoma, 117
nonspecificity of, 128
in papillary thyroid carcinoma, 128
in subacute thyroiditis, 38, 40
in undifferentiated thyroid carcinoma, 167, 168
in thyroid cysts, 107
in undifferentiated thyroid carcinoma, 166, 167, 175
Giant cell thyroiditis. See
Thyroiditis, subacute
Giant cell variant, of medullary thyroid carcinoma, 153, 157

Goiter
amyloid, 155–156
clinical management of, 63
definition of, 51
diffuse toxic. See Graves’ disease
dyshormonogenetic, 83
multinodular, 51
nodular, 51. See also
Adenomatous nodules, cellular
pathophysiology of, 51
Reidel’s thyroiditis-related, 31–32
relationship with follicular thyroid carcinoma, 64
size increase of, 9
Granules
in Graves’ disease, 74
in subacute thyroiditis, 38, 40
Graves’ disease, 74–76
as benign thyroid nodule
cause, 1
definition of, 74
distinguished from
follicular thyroid cancer, 74
papillary thyroid cancer, 139, 140, 142
enlarged nuclei in, 142
as thyroid carcinoma risk factor, 9

H
HBME-1, 143
Head and neck carcinoma,
metastatic squamous cell, 117, 164, 177
Hematoma, thyroid FNA-related, 15
Hemorrhage
in follicular lesions, 73
in thyroid cysts, 107
Hemosiderin-laden macrophages, 73, 106, 107, 108, 111
Histiocytes
in acute thyroiditis, 35
epitheloid (granulomas), 38, 39, 40
foamy, 100, 107
HMB45, as metastatic melanoma marker, 175, 177
Hodgkin’s disease, 32
“Honeycomb” sheets, of macrofollicular fragments, 57, 60, 62, 71, 68, 69
Hurthle cell carcinoma
clinical management of, 101
distinguished from Hurthle cell adenoma, 89, 91, 101
incidence of, 3
metastatic, prognosis for, 101–102
as percentage of all thyroid carcinomas, 88
screening test for, 88–89
Hurthle cell lesions, 88–102
differential diagnosis of, 95–100
general diagnostic approach to, 89, 91
Hashimoto’s thyroiditis-associated, 139
renal cell carcinoma as mimic of, 174
Hurthle cell neoplasms. See also Adenoma, Hurthle cell
algorithmic diagnostic approach to, 90
ancillary diagnostic tests for, 100–101
cystic degeneration of, 104, 107
cytologic features of, 91–96
diagnostic criteria for, 91–92
distinguished from adenomatous nodules, 89, 95, 96, 97, 98
Hashimoto’s thyroiditis, 47, 97, 96
medullary thyroid carcinoma, 96, 97, 98, 153, 154, 156–157, 158
metastatic renal cell carcinoma, 97, 100
papillary thyroid carcinoma, 98–100, 98, 100, 133, 134–135
parathyroid adenomas, 100
as “follicular neoplasms with oncocytic features,” 88
papillary, 98–100
single cell pattern of, 91, 92, 94, 100
“suspicious for” diagnostic category of, 91
Hurthle cells
in adenomatous nodules, 57, 58, 73, 82
cytologic features of, 90
in follicular thyroid lesions and neoplasms, 79–80, 89
granular cytoplasm in, 91, 92, 139
in Graves’ disease, 74
in Hashimoto’s thyroiditis, 35, 36, 37, 38, 47
metaplastic, nuclear enlargement in, 142
in subacute thyroiditis, 38
synonyms for, 88
Hyalinizing trabecular tumors, 138
Hypercellularity
of medullary thyroid carcinoma, 173
of metastatic disease, 172
of undifferentiated thyroid carcinoma, 169
Hyperplasia, parathyroid, 148
Hyperthyroidism, Graves’ disease-related, 74
Hypocellularity
of cystic papillary thyroid carcinoma, 111, 112
of medullary thyroid carcinoma, 156
of Reidel’s thyroiditis, 40, 41
of subacute thyroiditis, 38, 39, 40
Hypothyroidism
  Hashimoto’s thyroiditis-related, 30, 48–49
  Reidel’s thyroiditis-related, 31–32

I
  Immunoblasts, in lymphoma, 41, 43, 45
  Immunocytochemistry
    of cysts, 117–118
    of follicular thyroid lesions, 85–86
    of lymphoma, 48, 174, 175
    of medullary thyroid carcinoma, 148, 160–161
    of metastatic carcinoma, 166–167, 172–174, 175, 177
    of papillary thyroid carcinoma, 143
    of undifferentiated thyroid carcinoma, 175, 177
  Immunophenotyping, of lymphoma, 32, 43, 48, 174
  “Incidentaloma,” 9
  Indeterminate (suspicious), as diagnostic category, 26
  Inflammation, thyroid cyst-associated, 107
  Inflammatory thyroid lesions, 24. See also Thyroiditis
  algorithmic diagnostic approach to, 32, 34, 33
  ancillary diagnostic techniques for, 48
  clinical management of, 48–49
  diagnostic criteria for, 34–45
  diagnostic pitfalls regarding, 45–47
  differential diagnosis of, 31–32, 45–48
  prognosis for, 48–49
  Insular carcinoma, 5, 64, 80–82
  differential diagnosis of, 85
  as poorly-differentiated thyroid carcinoma, 80
  Iodine, radioactive. See
  Radioactive iodine therapy
  Iodine deficiency, as
  multinodular goiter cause, 51

K
  K-ras gene mutations, 120

L
  LCA (leukocyte common antigen), as lymphoma marker, 175
  Lobectomy
    as Hurthle cell carcinoma treatment, 101
    as “suspicious” papillary thyroid carcinoma treatment, 140, 143
  Lung cancer, metastatic to the thyroid, 164, 172–173, 177
  Lymph node dissection
    contraindication in follicular thyroid carcinoma, 86
    in medullary thyroid carcinoma, 162
  Lymph nodes, cervical
    metastatic medullary thyroid carcinoma of, 147
  Lymphocytes
    in Hashimoto’s thyroiditis, 35, 36, 38, 45
in lymphoma, 24, 34, 43–45
in subacute thyroiditis, 38
Lymphoglandular bodies, 35, 43, 175
Lymphohistiocytic aggregates, 35, 36, 38, 44, 45, 46
Lymphoid cells, immature, in diffuse large B-cell lymphoma, 41, 43
Lymphoid markers, for lymphoma, 175, 177
Lymphoma, thyroid, 24
algorithmic diagnostic approach to, 32–34
cytologic features of, 41–45
diffuse large (DLBCL), 32, 41–43, 49
distinguished from undifferentiated thyroid carcinoma, 174, 175
Follicular grade 4, 43
incidence of, 3
lymphocytes in, 24, 34, 43, 44
malignant, Hashimoto’s thyroiditis-related, 30
mantle cell, 44
of mucosa-associated lymphoid tissue (MALT), 32, 43–46
clinical management of, 49
differential diagnosis of, 45–47
immunophenotyping of, 48
non-Hodgkin’s B-cell, 32
primary, 32, 41, 43
Clinicopathologic features of, 32
Hashimoto’s thyroiditis-related, 48–49
T-cell, 32
World Health Organization subclassification system for, 48
Lymphoproliferative disorders, 32
M
Macrophages
in adenomatous nodules, 58, 72, 73
in cystic papillary thyroid carcinoma, 111, 112
in cysts and cystic degeneration, 23–24, 58, 59, 104, 111, 112
hemosiderin-laden, 73, 106, 107, 111
in papillary thyroid carcinoma, 121
tingible body, in Hashimoto’s thyroiditis, 46
Malignant, as diagnostic category, 26
Malignant melanoma, 158, 159
Marfanoid habitus, 148
MART-1, as metastatic melanoma marker, 175, 177

Medullary thyroid carcinoma, 147–162
clinical management of, 49
differential diagnosis of, 45–46
immunophenotyping of, 48
Multinucleated cells. See also
Giant cells, multinucleated
in medullary thyroid
carcinoma, 152, 153
Multiple endocrine neoplasia
syndromes (MEN), 9, 147, 148

N
Neck dissection, in medullary
thyroid carcinoma, 162
Necrosis/necrotic debris
in acute thyroiditis, 34–35
in metastatic disease, 172
in undifferentiated thyroid
carcinoma, 167, 169, 170, 171, 175
Needles, in fine-needle
aspiration, 12
internal diameter of, 56
Neuroendocrine carcinoma,
moderately
differentiated, 161
Neutrophils
in acute thyroiditis, 34–35, 47–48
in subacute thyroiditis, 38
Nodules, thyroid
adenomatous. See
Adenomatous thyroid
nodules
benign, 51–52
causes of, 1–2
cystic degeneration of, 103, 107–110
colloid, 51–52, 55, 56
dominant
Hashimoto’s thyroiditis-
related, 30
subacute thyroiditis-
related, 30–31
evaluation of, prior to fine
needle aspiration, 7–12
follicular, cystic degeneration
of, 107–110
goiter-related, 51
Hurthle cells in, 88–89
hyperplastic, Hashimoto’s
thyroiditis-related, 47–48
as “incidentalomas,” 9
isthmic, 11–12
nonneoplastic, synonymous
terms for, 52
nonpalpable, prevalence of, 1
palpable, prevalence of, 1
palpation and physical
examination of, 10–12
solitary
cystic, 103
follicular, 64
lymphoma-related, 32
medullary thyroid
carcinoma-related, 147
ultrasound imaging of, 7–8, 9
Nondiagnostic, as diagnostic
category, 26
Nuclear grooves
in cyst lining cells, 111
in follicular variant papillary
thyroid carcinoma, 131
in Hashimoto’s thyroiditis,
35, 37
in hyalinizing trabecular
tumors, 138
in papillary thyroid
carcinoma, 59, 126–127, 138, 157
Nuclear grooves (cont.)
  thin-layer preparation appearance of, 144
in ultimobranchial body cyst cells, 115
Nuclei
in adenomatous nodules, 58, 82–83
in cyst lining cells, 108, 110
  elongate, in Reidel’s thyroiditis, 40, 41
  enlarged
    in acute thyroiditis, 34–35
differential diagnosis of, 142
    in Graves’ disease, 139, 140, 142
    in Hashimoto’s thyroiditis, 142
    in metaplastic Hurthle cells, 142
    in papillary thyroid carcinoma, 121, 139, 139,
      142
    radioactive iodine therapy-related, 141
in squamous metaplasia, 142
in Hurthle cell neoplasms, 88, 91–92, 94, 157
in macrofollicular fragments, 57
in medullary thyroid carcinoma, 148, 152, 151,
  157
in papillary thyroid carcinoma, 58, 125
  in columnar cell variant, 136, 137, 138
  in follicular variant, 83, 131, 132
in tall cell variant, 136
  thin-layer preparation appearance of, 144, 145
  radioactive iodine therapy-related atypia of, 139,
    141, 142
in ultimobranchial body cyst cells, 115
in undifferentiated thyroid carcinoma, 167, 168, 169,
  170, 172, 175
Nucleoli
in acute thyroiditis, 34–35
in Hashimoto’s thyroiditis, 35
in Hurthle cell neoplasms, 91, 92, 96
in medullary thyroid carcinoma, 152, 153
in parathyroid carcinoma, 125–126
  red, in medullary thyroid carcinoma, 152, 153
in renal cell carcinoma, 174

O
Oncocytes. See Hurthle cells
Oncocytic metaplasia, in follicular lesions, 73
Oncocytic variants
  of medullary thyroid carcinoma, 133, 154–155
  of papillary thyroid carcinoma
differential diagnoses of, 98, 100, 131, 133, 134, 139,
  157
  nuclear features of, 83, 133
“Orphan Annie eye,” 125
Ossification, in follicular lesions, 73
Oxyphilic cells, 88
Palpation, of thyroid nodules, 10–12

Pancytokeratin, 143

Papanicolaou (Pap) smears, 18
- Amyloid appearance on, 155–156
- Colloid appearance on, 54, 55, 72, 69, 73
- Of papillary thyroid carcinoma
- Chromatin appearance on, 125, 126–127
- Nuclear groove appearance on, 126, 127

Papanicolaou Society, 23–24

Papillae, in papillary thyroid carcinoma, 157

Papillary thyroid carcinoma, 120–146
- Algorithmic diagnostic approach in, 122
- Clinical management of, 121
- Columnar cell variant of, 121
- Cystic, 59, 103, 104, 106–107, 110–112, 117, 121
- False-negative diagnosis of, 116
- Diagnostic criteria for, 121–131
- Chromatin features, 125–127
- Low-magnification appearance, 121–124
- Multinucleated giant cells, 128, 131
- Nuclear grooves, 126, 127
- Nuclear pseudoinclusions, 126–127, 128
- Nuclear size and shape, 123
- Psammoma bodies, 128, 130, 131
- "Ropey"/"bubble gum," 128, 131
- Squamoid cytoplasm, 128
- Differential diagnosis of, 138–141
- Diffuse sclerosing variant of, 120, 134
- Distinguished from colloid-predominant lesions, 59
- Cystic lesions, 24
- Hashimoto’s thyroiditis, 139
- Hurthle cell neoplasms, 96, 98–100
- Insular carcinoma, 84–85
- Medullary thyroid carcinoma, 156, 157–159
- Thyroiditis, 47
- Ultimobranchial body cysts, 117
- Epithelium-predominant, 121
- False-negative diagnosis of, 131
- Follicular variant of, 65, 121, 131, 133
- Differential diagnosis of, 131
- Nuclear features of, 83, 131, 132, 133
- General diagnostic approach to, 121
- Genetic features of, 120, 125, 143
- Incidence of, 3
- “Indeterminate,” 140
- Metastatic, 120, 145
Papillary thyroid carcinoma (cont.)
nuclear enlargement in, 121, 138–139
occult, in cystic lesions, 23–24
oncocytic (oxyphilic) variant of
differential diagnoses of, 98, 133, 134, 140, 157
nuclear features of, 133, 134
“Orphan Annie eye” appearance of, 125
as percentage of all thyroid carcinomas, 27, 120
prognosis for, 144–145 recurrent, 120
relationship with hyalinizing trabecular tumors, 138
“suspicious” (indeterminate) diagnostic category of, 140, 143
tall cell variant of, 120, 135–136, 137, 145
distinguished from Hurthle cell neoplasms, 100
thin-layer preparations of, 144, 145
treatment for, 120
Warthin’s-like variant of, 134–135

Papillary thyroid microcarcinoma, 146
Papillary variant, of medullary thyroid carcinoma, 155, 157

Paraneoplastic syndromes, medullary thyroid carcinoma-related, 147

Parathormone (parathyroid hormone), 117
Pheochromocytoma, 148

Physical examination, of the thyroid, 10–12
Pigmented cells/pigmentation in follicular thyroid lesions, 73
in medullary thyroid carcinoma, 153
Plasma cells
in Hashimoto’s thyroiditis, 35, 38, 45
in subacute thyroiditis, 38
in Warthin’s-like papillary thyroid carcinoma, 135
Plasmacytoid appearance, of Hurthle cell neoplasms, 92, 93
Plasmacytoid cells
in medullary thyroid carcinoma, 150, 152
in mucosa-associated lymphoid tissue (MALT) lymphoma, 43
Plasmacytoma, 32
Polygonal cells
in Hurthle cell neoplasms, 91, 92
Hurthle cells as, 88
in medullary thyroid carcinoma, 153, 154
in undifferentiated thyroid carcinoma, 166
Polymerase chain reaction, 161
Poorly-differentiated thyroid carcinoma
insular carcinoma as, 80
prognosis for, 5
PPARgamma gene, as follicular thyroid lesion marker, 85
Psammoma bodies
in cystic papillary thyroid carcinoma, 116
in diffuse sclerosing papillary thyroid carcinoma, 134
in papillary thyroid carcinoma, 128, 130, 131
Pseudofollicles, in medullary thyroid carcinoma, 148
Pseudoinclusions, nuclear
in hyalinizing trabecular tumors, 138
in medullary thyroid carcinoma, 152
in papillary thyroid carcinoma, 58, 117, 121, 126–127, 128, 138
thin-layer preparation appearance of, 144
in undifferentiated thyroid carcinoma, 169
p27 (KIP1), as follicular thyroid lesion marker, 85

R
Radiation exposure, as follicular thyroid carcinoma risk factor, 64
Radioactive iodine therapy
for Hurthle cell carcinoma, 101
as nuclear enlargement and atypia cause, 139, 141, 142
for papillary thyroid carcinoma, 120, 145
as thyroid carcinoma cause, 9
Radionuclide scans, of thyroid nodules, 7
Renal cancer, metastatic to the thyroid, 164, 172–173, 176
Renal cell carcinoma, metastatic to the thyroid, 172–173, 174, 176
distinguished from Hurthle cell neoplasms, 97, 100
RET proto-oncogene, 120, 125, 138, 143, 147, 161

S
Sarcoidosis, 46, 47
Sarcoma, distinguished from undifferentiated thyroid carcinoma, 164
Serum, similarity to watery colloid, 54
Signet-ring cells, in follicular thyroid neoplasms, 79–80
Single cell pattern
of Hurthle cell neoplasms, 91, 92
of lymphoma, 175
of malignant melanoma, 173
of medullary thyroid carcinoma, 147, 148, 157, 172, 173, 175
of metastatic disease, 159–160
of undifferentiated (anaplastic) thyroid carcinoma, 164, 167
of undifferentiated thyroid carcinoma, 164–166, 167, 175
Skeletal muscle fragments, similarity to dense colloid, 54
Small cell carcinoma,
distinguished from medullary thyroid carcinoma, 159
Small cells, in medullary thyroid carcinoma, 153–154
Small cell variant, of medullary thyroid carcinoma, 154
S-100
  as diffuse B-cell lymphoma marker, 46
  as metastatic melanoma marker, 175, 177
  as papillary thyroid carcinoma marker, 143
Specimens, in fine needle aspirations (FNA)
  assessment of adequacy of, 23–24
  assessment of general components of, 24
  processing of, 17–20
    of Cytospins, 18
    of direct smears, 18, 20
    of thin-layer preparations, 19–20
Spindle cell carcinoma, 159
Spindle cell variant, of medullary thyroid carcinoma, 154, 157, 159
Spindle/spindled cells
  in adenomatous nodules, 82
  bland, in Reidel’s thyroiditis, 40, 41, 47–48
  cyst lining cells as, 108, 109
  in medullary thyroid carcinoma, 151, 152–153, 154, 156
  in undifferentiated thyroid carcinoma, 166, 167, 168, 175
Squamoid/squamous cells
  in branchial cleft cysts, 118
  in medullary thyroid carcinoma, 153
  in thyroglossal duct cysts, 114
in undifferentiated thyroid carcinoma, 167, 175
Squamous cell carcinoma, of the head and neck, 117, 164, 173–174
Squamous metaplasia
  in adenomatous nodules, 82
  in follicular lesions, 73
  in Hashimoto’s thyroiditis, 35
  nuclear enlargement in, 142
Staphylococcus aureus, as acute thyroiditis cause, 31
Streptococcus sp., as acute thyroiditis cause, 31
Suspicious (indeterminate), as diagnostic category, 26
Synaptophysin, 143

T
Tall cells, in papillary thyroid carcinoma, 135–136, 137
Thin-layer preparations, 55
  of adenomatous nodules, 60–62, 63
  of Hurthle cell neoplasms, 100–101
  of papillary thyroid carcinoma, 140
  processing of, 19–20
ThinPrep, 55
Thyroglobulin
  as Hurthle cell neoplasm marker, 98–100, 157, 161
  during radioactive iodine therapy, 101
  as papillary thyroid carcinoma marker, 143
  as recurrent papillary thyroid carcinoma marker, 145
as undifferentiated thyroid carcinoma marker, 174, 175, 177

Thyroglossal duct cysts, 103, 104, 113–114, 114
distinguished from follicular-derived thyroid cysts, 117

Thyroid carcinoma. See also specific types of thyroid carcinoma
incidence of, 2–3
risk factors for, 9–10
subtypes of, 3

Thyroidectomy
for medullary thyroid carcinoma prevention, 162
as papillary thyroid carcinoma treatment, 120
partial, as goiter treatment, 63
thyroid cancer detected during, 2
total
as goiter treatment, 63
as Hurthle cell carcinoma treatment, 101
as medullary thyroid carcinoma treatment, 162
as papillary thyroid carcinoma treatment, 140, 145

Thyroid gland, physical examination of, 10–12

Thyroiditis, 30–41
acute, 31, 34–35
chronic lymphocytic. See Thyroiditis, Hashimoto’s
definition of, 30
de Quervain’s. See Thyroiditis, subacute
giant cell. See Thyroiditis, subacute
Hashimoto’s (chronic lymphocytic), 1, 24, 30
branchial cleft-like cysts associated with, 114
clinical management of, 48–49
cytologic features of, 33–38, 47
distinguished from Hurthle cell neoplasms, 47–48, 89, 96, 97, 98
distinguished from mucosa-associated lymphoid tissue lymphoma, 45–46
distinguished from papillary thyroid carcinoma, 139
distinguished from Warthin’s-like papillary thyroid carcinoma, 139
enlarged nuclei in, 142
fibrosing variant of, 33–35
Hurthle cell lesions associated with, 139
Hurthle cells in, 92, 96
as hypothyroidism cause, 48–49
lymphoma associated with, 3
as thyroid carcinoma cause, 9
ultimobranchial body cysts associated with, 114
Thyroiditis (cont.)

invasive fibrous. See Thyroiditis, Reidel’s, 31–32
multinucleated giant cells in, 128
palpation, 46, 128
Reidel’s, 24, 31–32, 34, 40–41
distinguished from undifferentiated carcinoma, 47–48
prognosis for, 48–49
subacute, 24, 30–32, 128
clinical management of, 48–49
cytologic features of, 38–40, 47
focal, 2
recurrent, 49
subacute granulomatous. See Thyroiditis, subacute

Thyroid peroxidase, as follicular thyroid lesions marker, 85

Thyroid-stimulating hormone, 7, 51

T lymphocytes, in Hashimoto’s thyroiditis, 35

Trachea, inadvertent FNA sampling of, 16

TTF-1, 143

as Hurthle cell neoplasm marker, 98–100
as medullary thyroid carcinoma marker, 160, 161, 175
as undifferentiated thyroid carcinoma marker, 174, 175, 177

Tuberculosis, 46, 47, 128

U

Ultimobranchial body cysts, 104, 114, 114–115, 117–118

Ultrasound, thyroid, 7–8, 104, 106

Undifferentiated (anaplastic) thyroid carcinoma, 164–178
algorithmic diagnostic approach to, 165
clinical management of, 177–178
development from well-differentiated thyroid carcinoma, 166
diagnostic criteria for, 167–172
differential diagnosis of, 83, 172–173, 175, 176
distinguished from acute thyroiditis, 34
insular carcinoma, 84–85
medullary thyroid carcinoma, 157–160
Reidel’s carcinoma, 47–48
general diagnostic approach to, 164, 166–167
immunocytochemistry of, 177
incidence of, 2–3
palliative therapy for, 164
prognosis for, 5, 164, 177–178
single cell pattern of, 164, 167
Unsatisfactory, as diagnostic category, 26

V

Vasovagal experience, thyroid FNA-related, 15

Viral infections, as thyroiditis cause, 30
W
Well-differentiated thyroid carcinoma
follicular, 64
prognosis for, 5
undifferentiated thyroid carcinoma development from, 164, 166

World Health Organization subclassification system, for thyroid lymphoma, 48